Author  
Place of duty  
Title   진행성 또는 재발성 자궁경부암에서 Cislatin , Vincristine , Bleomycin , Methotrexate ( PVBM ) 복합화학요법 ( Cislatin , Vincristine , Bleomycin and Methotrexate ( PVBM ) Combination Chemotherapy for Advanced Uterine Cervix Cancer )
Publicationinfo   1990 Jan; 022(03): 505-518.
Key_word   Uterine cervix cancer, Chemotherapy
Full-Text  
Abstract   Twenty-nine patient with advanced cervix cancer were treated with a combination chemotherapy of cisplatin, vincristine, bleomycin, and methotrexate between January, 1987 and December, 1988. 1) Among 19 evaluable patients, 4 patients (20.1%) achieved complete response and 6 patients (31. 6%) achieved partial response, giving an overall response rate of 51.7%. The median duration of remission was 23 weeks in the responders. 2) The median survival of overall patients was 50 7 weeks. The median survival of the responders did not reach the median value during the follow-up period of 15-81 weeks. In contrast, the median survival of the non-responders was 30.7 weeks, which was significantly shorter than that of the responders (p<0.05). 3) The only factor influencing remission rate was the pattem of failure, and the patients with distant metastasis showed higher remission rates (p<0.01). There were no prognostic factors influencing the remission duration. The factors improving survival rates were the early stage at diagnosis (p< 0. 005), the previous history of curative operation (p<0.005), and the presence of distant metastasis (p<0.01). 4) Considerable number of patients experienced toxicities. Among these, leukopenia (50%) and thrombocytopenia (4.7%) were the main hematologic toxicities. Most patients experienced nausea, vomiting, diarrhea (89.49o), stomatitis (26 3%), and alopecia (73.7%). Neurotoxicity due to vincristine or cispatin was found in 36.896 of patients, and 2 patients showed pulmonary fibrosis due to bleomycin toxicity. In conclusion, this regimen (PVBM) seems to be effective in terms of remission rates, but did not show any additional benifits in terms of remission duration or overall survival. In addition, the large number of patients experienced considerable side effects. Based on these findings, further studies are needed to find out the new regimen which is more effective and less toxic for the patients with advanced uterine cervix cancer.
저 자   임영혁(Young Hyuk Im),이기형(Kee Hyung Lee),박영석(Young Suk Park),서창인(Chang In Suh),강원기(Won Ki Kang),김효진(Hyo Jin Kim),김홍태(Heung Tae Kim),허대석(Dae Seog Heo),방영주(Yung Jue Bang),김노경(Noe Kyeong Kim),강순범(Soon Beom Kang),이효표(Hyo Pyo Lee),이진용(Jin Yong Lee),김승욱(Seung Wook